- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03042819
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)
This is a phase 1b study of investigational drug selinexor in combination with doxorubicin in patients with locally advanced or metastatic soft tissue sarcoma. The purpose of this study is to determine how safe and tolerable the combination is, as well as the best dose of the study drugs in this patient population.
Selinexor (also called KPT-330), works by trapping "tumor suppressor proteins" within the cell and thus causing the cancer cells to die or stop growing.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a phase 1b study of investigational drug selinexor in combination with doxorubicin in patients with locally advanced or metastatic soft tissue sarcoma.
Patients will be screened for eligibility within 28 days of the start of the study drugs. In addition to standard tests and procedures, research tumor tissue (archival or fresh biopsy) will be collected for collection for pharmacodynamics. Participants will also be asked if they agree to optional biopsies at 6 cycles if their cancer is responding and at disease progression.
Eligible participants will then receive the study drugs in 21 day cycles. Selinexor will be given by mouth and doxorubicin will be given by vein, once a week, for 6 cycles.
Participants will be restaged every 2 cycles. If participants respond to treatment after 6 cycles, they may be able to continue the selinexor alone as a maintenance treatment until progression or unacceptable toxicity.
While receiving the study drug, many of the screening tests will be repeated. Additional tests and procedures include blood sample collection for pharmacokinetics and pharmacodynamics.
When participants stop the study drug permanently for any reason, an end of treatment visit, 28-day follow-up, and long term follow up every 90 days will occur.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- Princess Margaret Cancer Centre
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written informed consent
- Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- Age ≥ 18 years.
- Patients must have histologically confirmed locally advanced/unresectable or metastatic soft tissue sarcoma.
- Patients must have not received prior doxorubicin.
- Patient must show evidence of progressive disease on study entry or newly diagnosed patients with de novo metastatic measurable disease
- Patient must have measureable disease as defined by RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Adequate hematopoietic function
- Adequate hepatic function:
- Adequate renal function
- Adequate cardiac function13
- Patients must agree to use methods of contraception as a agreed upon by the patient and study doctor
Exclusion Criteria:
- Patient is pregnant or lactating
- Radiation, chemotherapy, immunotherapy, any other systemic anticancer therapy, or participation in an investigational anti-cancer study ≤3 weeks prior to initiation of therapy.
- Major surgery within 4 weeks before initiation of therapy
- Unstable cardiovascular function
- Active, ongoing or uncontrolled active infection within one week prior to first dose.
- Malignancies other than disease under study within 2 years prior to Cycle 1, Day 1.
- Known to be HIV seropositive
- Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) RNA or hepatitis B virus (HBV) surface antigen (HBsAg)
- Patients with active CNS malignancy.
- Patients with any gastrointestinal dysfunctions that could interfere with the absorption of Selinexor or patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea.
- Inability or unwillingness to take supportive medications such as anti-nausea and anti anorexia agents.
- In the opinion of the Investigator, patients who are significantly below their ideal body weight
- Serious psychiatric or medical conditions that could interfere with treatment
- Concurrent therapy with approved or investigational anticancer therapeutic agents
- Any condition that, in the opinion of the Investigator, would interfere with evaluation of the study regimen or interpretation of patient safety or study results
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Selinexor plus Doxorubicin
Selinexor will be given by mouth (orally) once a week: Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks. |
Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
Doxorubicin is currently approved for various cancers.
Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix.
These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
To evaluate the Incidence of Treatment-Emergent Adverse Events, graded and categorized according to the CTCAE v4.0.
Periodo de tiempo: 3 years
|
All adverse events will be tabulated and summarized by major organ category, grade, anticipation, and drug attribution.
SAE specific incidence and exact 95% confidence interval will be provided where appropriate.
|
3 years
|
To determine the recommended phase II dose (RP2D) of Selinexor in combination with doxorubicin
Periodo de tiempo: 3 years
|
The RP2D will be determined according to interim mTPI monitoring algorithm (Figure 5.1) using the dose determining set.
|
3 years
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Tasa de respuesta
Periodo de tiempo: 3 años
|
3 años
|
Rate of Grade 3 Toxicities
Periodo de tiempo: 3 years
|
3 years
|
Progression-free Survival Rate
Periodo de tiempo: 3 years
|
3 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Albiruni Razak, M.D., Princess Margaret Cancer Centre
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SAR-002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Selinexor
-
Karyopharm Therapeutics IncBelgium and Luxembourg Gynaecological Oncology Group; North-Eastern German Society... y otros colaboradoresActivo, no reclutandoCáncer endometrialEstados Unidos, Porcelana, Israel, España, Bélgica, Alemania, Grecia, Chequia, Italia, Canadá
-
Karyopharm Therapeutics IncGOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT) y otros colaboradoresReclutamientoCáncer endometrialEstados Unidos, Bélgica, España, Israel, Australia, Italia, Georgia, Irlanda, Grecia, Eslovaquia, Canadá, Hungría, Chequia
-
Memorial Sloan Kettering Cancer CenterReclutamientoTumor solido | Tumor rabdoide | Tumor de Wilms | Nefroblastoma | Tumores malignos de la vaina del nervio periférico | MPNST | Mutación del gen XPO1Estados Unidos
-
The First Hospital of Jilin UniversityReclutamientoPacientes con PTCL que lograron una respuesta completa del tratamiento de primera líneaPorcelana
-
University of RochesterKaryopharm Therapeutics IncReclutamientoMieloma múltiple latenteEstados Unidos
-
University of UtahKaryopharm Therapeutics IncActivo, no reclutandoMielofibrosis primaria | Post-policitemia Vera Mielofibrosis | Mielofibrosis post-trombocitemia esencialEstados Unidos
-
National University Hospital, SingaporeKaryopharm Therapeutics IncTerminado
-
Karyopharm Therapeutics IncTerminadoNeoplasias malignas hematológicasEstados Unidos, Dinamarca, Canadá
-
Karyopharm Therapeutics IncTerminadoTransformación de RichterEstados Unidos, Alemania, Reino Unido, España, Polonia
-
Morten Mau-SoerensenHospices Civils de Lyon; Gustave Roussy, Cancer Campus, Grand Paris; Institut Curie y otros colaboradoresDesconocidoTimoma | Tumor epitelial tímico avanzadoDinamarca, Francia